| Date | Title | Description |
| 14.05.2025 | BioCentury to Host Grand Rounds in Chicago: Where Translational Science Meets Investors and Dealmakers | Join VCs, academic innovators and biopharma executives to connect, collaborate and accelerate innovation at the forefront of drug R&D
CHICAGO–(BUSINESS WIRE)–May 14, 2025–
Top decision-makers from across the biopharma ecosystem will con... |
| 20.01.2025 | Umoja Biopharma's $100 Million Leap: A New Era for In Vivo CAR T Cell Therapies | Umoja Biopharma is on the rise. The Seattle-based company has just secured $100 million in Series C financing. This is not just a number; it’s a statement. It signals a bold step forward in the world of biotechnology. The funding round was ... |
| 20.01.2025 | Umoja Biopharma Raises $100M in Series C Financing | Umoja Biopharma, a Seattle, WA-based clinical-stage company which specializes in vivo cell therapies, raised $100M Series C financing.
The round was led by Double Point Ventures and DCVC Bio, with participation from new and existing investo... |
| 19.06.2024 | ElevateBio: компания по производству генетических лекарств | Содержание
История компании
Технологии: объединение производства и некстген технологий терапевтического производства
Экосистема компании
BaseCamp
Партнеры
Отраслевые партнерства
Академические партнерства
Привлечение инвестиций История компа... |
| 21.05.2024 | AKTIS ONCOLOGY ENTERS INTO STRATEGIC COLLABORATION WITH LILLY TO DISCOVER AND DEVELOP NOVEL ANTICANCER RADIOPHARMACEUTICALS | Collaboration to utilize Aktis Oncology's proprietary miniprotein discovery platform to generate novel tumor-targeting radiopharmaceuticals
Aktis responsible for program discovery through initial human imaging studies; Lilly responsible for... |
| 16.10.2023 | AstronauTx, developing treatments for Alzheimer's, raises $59M Series A | The startup works in partnership with UCL and is backed by Novartis and UK gov't funds
In the United States alone, about 10.7% of people age 65 and older are living with Alzheimer's – the most common form of dementia. That number is project... |
| 06.10.2021 | Facebook’s outage becomes a boon for other social media startups | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox.
What is one man’s loss is another man’s gain.
Paid Content Why pay equity is core to Capital One'... |
| 06.10.2021 | Facebook’s outage becomes a boon for other social media startups | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox.
What is one man’s loss is another man’s gain.
Paid Content PwC is teaching businesses the power o... |
| 26.02.2020 | MPM Capital Announces $100M Oncology Innovations Fund as Part of Novel Venture Philanthropy Collaboration with Dana-Farber Cancer Institute | - |
| 26.02.2020 | WSJ.com – MPM Capital Raises $100 Million Fund, Teams Up With Dana-Farber Cancer Institute | - |
| 17.12.2019 | In novel partnership with cancer group, biotech venture firm doles out grants for research | The whole point of a biotech venture capital firm is to make money for itself and its investors. But one fund is doing something counterintuitive: giving away some of its money.
On Tuesday, Boston-based venture firm MPM Capital and the Amer... |
| 25.02.2019 | Impact investing: a new way to fund cures for cancer | Impact investing is changing the world, offering socially conscious investors opportunities to drive social and environmental change without sacrificing financial returns. It’s become common in sectors like renewable energy and education. B... |
| 21.02.2019 | Scrip Pharma intelligence: MPM Raises $400M To Build Early-Stage Biotechs | - |
| 21.02.2019 | MPM Capital Raises $400 Million to Fund Early-Stage Biotech Innovation | - |
| 21.02.2019 | MPM Capital Raises $400M to Fund Early-Stage Biotech Innovation | MPM Capital, a Cambridge, MA – and Brisbane, CA-based life-sciences venture capital firm investing in early-stage therapeutics companies, closed its seventh venture fund, at $400m.
With BioVentures 2018, MPM will continue to create and inve... |
| 21.02.2019 | Term Sheet — Thursday, February 21 | LYFT PREDICTIONS
Good morning, Term Sheet readers.
Paid Content Securing the enterprise without boundaries From ExtraHop
Ride-hailing giant Lyft is preparing to list its shares on the Nasdaq near the end of March, according to The Wall Stre... |
| 06.12.2018 | NIH is pressed to ensure affordable pricing before awarding a license for a CAR-T therapy | A plan by the National Institutes of Health to award an exclusive license for a CAR-T therapy that was funded by U.S. taxpayers to a group of biotech venture capitalists has sparked concerns among advocacy groups over pricing and access in ... |
| 20.06.2018 | MPM Leads $75 Million Series B Financing of iTeos Therapeutics | - |
| 18.04.2018 | MPM Capital Portfolio Company Tetherex Pharmaceuticals Completes $50M Series B Financing | - |
| 13.08.2017 | MPM Capital-backed Maverick Therapeutics Appoints James Scibetta as CEO | BRISBANE, Calif.–(BUSINESS WIRE)–Maverick Therapeutics Inc., a private immuno-oncology company pioneering advances in redirected T cell therapeutics, announced the appointment of James S. Scibetta as Chief Executive Officer and a member of ... |
| 13.08.2017 | MPM Capital-backed Maverick Therapeutics Appoints James Scibetta as CEO | BRISBANE, Calif.–(BUSINESS WIRE)–Maverick Therapeutics Inc., a private immuno-oncology company pioneering advances in redirected T cell therapeutics, announced the appointment of James S. Scibetta as Chief Executive Officer and a member of ... |
| 25.05.2017 | MPM Capital Joins $45M Series B for Harpoon Therapeutics | Harpoon Therapeutics said it raised $45 million of Series B financing in a deal co-led by Arix Bioscience and New Leaf Venture Partners and joined by new investor Taiho Ventures and existing investor MPM Capital.
Arix Investment Manager Mar... |
| 09.02.2017 | MPM Capital Appoints Chris Varma as Entrepreneur-in-Residence | South San Francisco, CA- and Cambridge, MA-based early-stage life sciences venture capital firm MPM Capital has appointed Chris Varma, PhD, as Entrepreneur-in-Residence.
In this role, Varma will primarily be responsible for advancing MPM’s ... |
| 05.01.2017 | Biotech Investor Ed Hurwitz Joins MPM Capital as Managing Director | Early-stage life sciences venture firm MPM Capital has expanded its San Francisco based investment team with the appointment of Ed Hurwitz, JD, MBA, as Managing Director.
With more than 25 years of biotech and life science investment, finan... |
| 10.11.2016 | How does 23andMe make money? | The genetics company sells a DNA analysis kit to consumers and collaborates with researchers
Editor's note: Our Post Seed VC event is coming up on Dec. 1 in San Francisco. We'll have Chamath Palihapitiya (Founder of Social Capital), Aydin S... |
| 12.08.2016 | Digital Health Investment Firm DigiTx Partners Launches | Astellas Pharma, a Tokyo, Japan-based company dedicated to develop pharmaceutical products focusing on Urology, Oncology, Immunology, Nephrology and Neuroscience, has partnered with MPM Capital* to launch DigiTx Partners, a digital health i... |
| 01.08.2016 | Japan: Astellas, MPM Capital form venture firm DigiTx Partners | Premium
Japanese firm Astellas Pharma Inc, in partnership with US-based MPM Capital Inc, have launched a new digital health investment company named the DigiTx Partners.
Continue reading this story with a subscription to DealStreetAsia.
Sub... |
| 31.07.2016 | Astellas and MPM Capital Launch DigiTx Partners | TOKYO & SAN FRANCISCO–(BUSINESS WIRE)–Astellas Pharma Inc. and DigiTx Partners LLC announce that Astellas has launched DigiTx Partners, a digital health investment company in partnership with MPM Capital, Inc. DigiTx Partners will inves... |
| 29.07.2016 | Former Lumiata COO leads pharma-backed investment firm targeting digital health startups | Would you liken your firm to SR One but focused on digital health?
Unlike SR One, we are not a corporate arm of a pharma company but an independent financing company that has been funded by pharma and MPM Capital. Moreover, we will not be a... |
| 03.05.2016 | MPM Launches $471 Million Social Impact Oncology Fund | - |
| 03.12.2015 | Daily funding roundup - Dec. 3, 2015 | True North Therapeutics bagged $40M; Allocadia raised $16.5M; Younity received $8M funding
Younity, an iOS app for streaming media from your Mac, today announced an $8 million Series A round of funding led by venture capital firm Marker LLC... |
| 14.05.2015 | MPM closes $400 million fund | - |
| 23.04.2015 | Report: Mobile health app companies raised $220 million in Q1 | Glooko, which received FDA clearance for a mobile diabetes management app and a metersync device, raised $16.5 million from Medtronic, Canaan Partners, The Social + Capital Partnership and Samsung’s venture investment arm. The funding will ... |
| 24.03.2015 | Semma Therapeutics Announces $44 Million in Funding Led by MPM Capital to Develop Cell Therapy for Treating Type 1 Diabetes; Signs Agreement with Global Pharmaceutical Company | - |
| 24.03.2015 | Semma Therapeutics Announces $44 Million in Funding Led by MPM Capital to Develop Cell Therapy for Treating Type 1 Diabetes; Signs Agreement with Global Pharmaceutical Company | CAMBRIDGE, Mass.–(BUSINESS WIRE)–March 24, 2015–
Semma Therapeutics, a company developing a cell therapy for Type 1 diabetes, announced today that it has closed a $44 million Series A consisting of equity financing and strategic funding. Th... |
| 19.03.2015 | Clinical Ink, CentrosHealth Merge in Paperless Drug Trials Push | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
Clinical trials software company Clinical Ink is adding new mobile capabilities through a merger with CentrosHealth, in a deal that also comes with a capital infusion into the... |
| 09.12.2014 | MPM Capital-backed cancer immunotherapy startup Potenza Therapeutics raises $15M | It also looks like it’s prepping to move out of LabCentral and into a new lab space at 1030 Massachusetts Ave. in Cambridge, as it recently applied for a biosafety permit with the city. Riveting stuff.
The $15 million comes from five invest... |
| 16.04.2014 | Iconic Therapeutics Completes $20M Series B-1 Equity Financing | Iconic Therapeutics, Inc., a Atlanta, GA and South San Francisco, CA-based biotechnology company focused on developing therapeutics for serious eye disorders, completed a $20m Series B-1 equity financing.
Backers included new investors MPM ... |
| 25.11.2013 | FDA to 23andMe: Stop selling spit kits | . . . we still do not have any assurance that the firm has analytically or clinically validated the PGS for its intended uses, which have expanded from the uses that the firm identified in its submissions. In your letter dated January 9, 20... |
| 01.11.2013 | OrbiMed closes its largest VC fund, predicts rebound in healthcare investing in 2014 | Looking back 5 to 6 years, healthcare venture capital funds raised $7.8 billion, but last year they only raised $2.5 billion.
Silverstein and Carl Gordon, a partner and co-head of global private equity, told MedCity News they anticipate ple... |
| 30.10.2013 | Which venture capital firm’s healthcare investment picks secured the most IPOs? | I won’t get into Aratana Therapeutics (Nasdaq: PETX) because the biopharmaceutical company develops treatments for animals.
Acceleron Pharma: (Nasdaq: XLRN) raised $96.7 million after it priced at the high end of its share price range. The ... |
| 20.09.2012 | Selexys Pharmaceuticals Closes $23M Series A Equity Financing | Selexys Pharmaceuticals, an Oklahoma City, OK-based biopharmaceutical company, has closed a $23m Series A equity financing.
The round was led by MPM Capital.
Led by Dr. Scott Rollins, President and CEO, Selexys focuses on development of the... |
| 31.05.2012 | Is it time for the venture capital industry to ditch the 2-and-20 pay model? | “It’s interesting that VCs have positioned themselves as supporters, financers, and even instigators of innovation, yet there has been so little innovation within the VC industry itself,” the report states.
But moving away from 2-and-20 won... |
| 07.12.2011 | Aratana Therapeutics Closes $15M Series B Financing | Aratana Therapeutics, a Kansas City, KS-based animal health company developing innovative medicines for companion animals, has closed a $15m Series B financing.
Backers include existing investors MPM Capital, Avalon Ventures and Cultivian V... |
| 07.01.2011 | 23andMe adds $9M to Series C round | MPM Capital joins Johnson & Johnson in 23andMe's $31M Series C round
Personal genomics company 23andMe announced Friday morning that it has added another $9 million to its Series C round, bringing the total fundraising round to $31 mill... |
| 07.01.2011 | Funding roundup - week ending 01/07/11 | After the holiday slowdown, fifteen early- and late-stage startups raise altogether over $200M
Early-stage
Assistly, a provider of socially-networked customer service, has raised a $3 million second round of funding from Bullpen Capital, In... |
| 26.01.2010 | A new model for life-sciences venture firms? MedCity Morning Read, Jan. 26, 2010 | Promoted
Clinical Care Capacity Planning
Learn how to manage clinical care capacity more efficiently during uncertain times.
SAP
Promoted
Covid-19’s terrible toll on diabetes patients. What can be done?
The public health crisis has undermin... |
| 14.07.2009 | iZumi Bio merges with Pierian to fuel stem cell technology | iZumi Bio, a research firm specializing in stem-cell research used to create a range of treatments, has merged with a similar company, Pierian, to advance development of regenerative medical therapies. At the same time, the new entity — iPi... |
| 13.04.2009 | VCs already eyeing potential in new Chinese health care reforms | Last week, China’s State Council approved sweeping reform of its health care system, infusing it with $125 billion to provide universal medical coverage by 2011. And already venture capitalists all over the world are anticipating the opport... |
| 30.03.2009 | Essex Woodlands raises almost $1B for life science investments | Essex Woodlands Health Ventures announced today that it brought in $900 million for its eighth fund, one of the largest sums ever raised by a health care-focused venture firm, according to the Wall Street Journal — even more impressive cons... |
| 25.03.2009 | Neovista sees $18M to treat eye disorders | Neovista, a Fremont, Calif.-based biotech company specializing in eye diseases, says it raised $18 million in a fourth round of funding to commercialize its new device. The money came from Accuitive Medical Ventures, Carlyle Group, Essex Wo... |
| 27.01.2009 | Innovative Spinal Technologies Jilted, Now Bankrupt, Source Says | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
Last night we reported that Mansfield, MA-based Innovative Spinal Technologies, a maker of implants to correct degenerative spinal disorders, had gone dark—the company’s websi... |
| 26.01.2009 | What’s Up at Innovative Spinal Technologies? Everything Seems Down | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
When nobody answers a company’s phones and its website turns into a big fat 404 error, it can’t be a good sign. That seems to be the situation at Innovative Spinal Technologie... |
| 05.12.2007 | MPM says the game is afoot in India | MPM Capital, a VC firm headquartered in Boston and South San Francisco, Calif., wants to put Indian life-science firms on notice that it’s comin’ a-huntin’. The VC firm told reporters for VentureWire, Reuters and others that it plans to act... |
| 24.07.2007 | KaloBios draws in $20M for antibody drugs | KaloBios, a Palo Alto, Calif., biotech antibody-therapeutic company, raised $20 million in a third funding round. The company is developing new drugs based on monoclonal antibodies, which target specific cells or proteins in the body. Its l... |
| 12.06.2007 | Cleveland biotech Athersys raises $65M with reverse-merger | Athersys, a Cleveland, Ohio biotech, went public via reverse merger and raised $65 million in a private placement. The company’s release is here.
Founded in 1995, Athersys is active in a bewildering number of areas. Its lead product candida... |
| 29.05.2007 | EnteroMedics plans $86M IPO for obesity-control implants | EnteroMedics, a St. Paul, Minn., developer of obesity-treatment implants, filed to raise up to $86.25 million in an IPO. Its S-1 filing with the SEC is here.
The company is developing a neuromodulation implant called VBLOC that is designed ... |
| 18.05.2007 | Neosil raises $10M in debt for hair-growth product | Neosil, an Emeryville, Calif., company focused on dermatology products, raised a $10 million in venture debt from Hercules Technology Growth Capital. The debt funding follows the company’s $32 million first-round venture financing in 2004, ... |
| 08.05.2007 | Cardiovascular biotech Portola Pharmaceuticals raises $70M, eyes IPO | Portola Pharmaceuticals, a South San Francisco, Calif., biotech aiming to develop treatments for blood clots and other heart-related problems, raised $70 million in a third round of financing dominated by late-stage and public-market invest... |
| 04.05.2007 | Cancer-drug maker Aveo raises $53M | Aveo Pharmaceuticals, a Cambridge, Mass. cancer-drug company, raised $53 million in a fourth round of funding from a coalition of mostly blue-chip life-science investors.
New investors included Biogen Idec, Bessemer Venture Partners, Merlin... |
| 27.04.2007 | MPM goes after Indian healthcare companies | MPM Capital, a San Francisco venture capital firm focused on healthcare investments, has partnered with Indian biotechnology company Reliance Life Sciences to invest in India.
VentureWire has the story (sub required), and says it is signifi... |
| - | FDA to 23andMe: Stop selling spit kits | Star startup 23andMe got slammed with an FDA warning letter Nov. 22. The letter says the healthcare startup’s genetic testing spit kits are being marketed without clearance or approval. It goes so far as to say the diagnostics applications,... |
| - | Report: Mobile health app companies raised $220 million in Q1 | Apps to help manage chronic conditions and other illnesses dominated the $220 million raised across 35 deals, according to a new report sizing up the first quarter of 2015 by Mercom Capital. Mercom noted that app developers had raised about... |
| - | OrbiMed closes its largest VC fund, predicts rebound in healthcare investing in 2014 | OrbiMed has closed its largest venture capital healthcare fund to date as two partners predict a resurgence in biotech investment next year. The robust reception biotech initial public offerings have received this year is fueling this trend... |
| - | Is it time for the venture capital industry to ditch the 2-and-20 pay model? | The 2-and-20 compensation structure for venture capital funds is a one-size-fits-all approach that misaligns incentives and can help VCs to get paid handsomely while their funds perform abysmally.
That was one conclusion from a much–discuss... |
| - | A new model for life-sciences venture firms? MedCity Morning Read, Jan. 26, 2010 | Highlights of the important and the interesting from the world of health care:
A new model for life-sciences venture firms? Could a new investment company made of veterans from MPM Capital, OrbiMed Advisors, Pfizer Inc. and Morgan Stanley s... |
| - | MPM Capital-backed cancer immunotherapy startup Potenza Therapeutics raises $15M | Despite keeping publicly mum about the specifics of its approach, cancer immunotherapy startup Potenza Therapeutics has certainly piqued the attention of investors – it just raised $15 million, according to a regulatory filing.
But we don’t... |
| - | Novartis buys cancer immunotherapy startup co-founded by venture investors | A biotechnology company formed by two MPM Capital managing directors to develop monoclonal antibody drugs to fight cancer has been acquired by Novartis, according to a company statement. The move follows Novartis’ deal with University of Pe... |
| - | Which venture capital firm’s healthcare investment picks secured the most IPOs? | Biotechnology and healthcare companies have been going public at a good clip this year, at a rate that overshadows the past few years. But initial public offerings are not what they used to be. Although they used to mark an exit for a compa... |
| - | Former Lumiata COO leads pharma-backed investment firm targeting digital health startups | The convergence between digital health and pharmaceutical companies has been an interesting trend to witness in the past few years. Increasingly, pharma companies want to move from being customers of digital health companies to having a rol... |
